Publications by authors named "Ken Masubuchi"

Claim this Profile
A
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Tae Hata, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Ken Masubuchi

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Ken Masubuchi

Int J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
Toshiya Fujisaki, Eisaku Miyauchi, Gen Kida, Yu Miura, Kana Watanabe, Ken Masubuchi

Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer.
Ayako Shiono, Hisao Imai, Satoshi Endo, Shohei Okazaki, Takanori Abe, Ken Masubuchi

Mol Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).
Tomoya Fukui, Nobuaki Mamesaya, Toshiaki Takahashi, Kazuma Kishi, Takahiro Yoshizawa, Ken Masubuchi

J Thorac Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Ken Masubuchi

Target Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.
Satoshi Endo, Hisao Imai, Ayako Shiono, Kosuke Hashimoto, Yu Miura, Ken Masubuchi, Takeshi Masubuchi

Oncology· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Ken Masubuchi

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.
Satoshi Wasamoto, Hisao Imai, Takeshi Tsuda, Yoshiaki Nagai, Takayuki Kishikawa, Ken Masubuchi

Intern Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.
Ayako Shiono, Hisao Imai, Satoshi Endo, Kazuki Katayama, Hideaki Sato, Ken Masubuchi

Radiol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial.
Hirotoshi Iihara, Masamichi Iwai, Ryo Morita, Yukiyoshi Fujita, Keiko Ohgino, Ken Masubuchi

Lung Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Fuyumi Nishihara-Kato, Hisao Imai, Takeshi Tsuda, Satoshi Wasamoto, Yoshiaki Nagai, Ken Masubuchi

Oncology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Takayuki Kishikawa, Ken Masubuchi

Thorac Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Ken Masubuchi, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Hiroyuki Minemura

Thorac Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer.
Hisao Imai, Ryoichi Onozato, Kyoichi Kaira, Sayaka Kawashima, Ken Masubuchi

Oncology· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy.
Hisao Imai, Daijiro Kobayashi, Kyoichi Kaira, Sayaka Kawashima, Ken Masubuchi

Radiol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.
Hisao Imai, Kyoichi Kaira, Ken Masubuchi, Koichi Minato

Curr Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival.
Hisao Imai, Ryoichi Onozato, Kyoichi Kaira, Sayaka Kawashima, Ken Masubuchi

Thorac Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutathione redox regulates TGF-beta-induced fibrogenic effects through Smad3 activation.
Akihiro Ono, Mitsuyoshi Utsugi, Ken Masubuchi, Tamotsu Ishizuka, Tadayoshi Kawata

FEBS Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-Jun-NH2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-beta1 in human lung fibroblasts.
Mitsuyoshi Utsugi, Kunio Dobashi, Tamotsu Ishizuka, Ken Masubuchi, Yasuo Shimizu

Am J Respir Cell Mol Biol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ambroxol inhibits platelet-derived growth factor production in human monocytic cells.
Mitsuyoshi Utsugi, Kunio Dobashi, Yasuhiko Koga, Ken Masubuchi, Yasuo Shimizu

Eur J Pharmacol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis